InvestorsHub Logo

scottsmith

10/31/16 6:59 AM

#390 RE: Citrati #389

We made the big time now boys.

C I'm gonna try to take your advice and accumulate those free shares here. The way to wealth! Got a nice 40 percent gain here earlier in the year but sold all. I think under your philosophy I shoulda sold most and kept a little.

noretreat

10/31/16 9:55 AM

#393 RE: Citrati #389

Every time I read about the pipeline listed below, I can't help but think that this company is undervalued by quite a bit. I recently had some communication on RedHill with some investors from Europe, and they remain very high on the prospects.

I am very confident about the science and have come away from talks with management thinking about how to best acquire a maximum position. Day to day distractions are not getting in my way on this one.

Some think the pipeline for CTIX is impressive. Well, here is the pipeline summary for RedHill:

RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) is a biopharmaceutical company headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill’s current pipeline of proprietary products includes: (i) RHB-105 - an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii) RHB-104 - an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study and an ongoing proof-of-concept Phase IIa study for multiple sclerosis; (iii) BEKINDA® (RHB-102) - a once-daily oral pill formulation of ondansetron with an ongoing Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA™ (ABC294640) - a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON - a Phase II-stage first-in-class, orally-administered uPA inhibitor, targeting gastrointestinal and other solid tumors; (vii) RP101 - currently subject to an option-to-acquire by RedHill, RP101 is a Phase II-stage first-in-class, orally-administered Hsp27 inhibitor, targeting pancreatic and other gastrointestinal cancers; (viii) RIZAPORT® (RHB-103) - an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015; and (ix) RHB-101 - a once-daily oral pill formulation of the cardio drug carvedilol.

noretreat

10/31/16 10:02 AM

#395 RE: Citrati #389

to directly answer your question...

In my view RedHill is a prime acquisition target.

Citrati

10/31/16 1:14 PM

#398 RE: Citrati #389

Need to correct a possible error..... that july 11 gap did close on the 14th.
What makes it of interest still is that 11.51 price low in Dec 2015 which it came within .01 of hitting on this low volume drop today and corresponding supply candle in that time period. This "could" be our low hitting that and rising after 4 days below the lower bb.
It is now up to that s-3 pivot at 12.18 and the 200 day at 12.22 to see whether support or resistance forms. Nothing is certain until confirmed.
Best wishes for green to all.
RDHL

123tom

10/31/16 9:41 PM

#402 RE: Citrati #389

Citrati,is this chart a range pattern?

a giant range maybe? but still, its been way up and way down. I cant really see any other shape. could it fall again to 8 dollars. ?



Resistance shoulders get Hammered down at 16 and 17 dollars.... and support shoulders get bought at 8/9 and 10